Abstract: Improved RP-HPLC methods for purifying recombinant betainterferon are disclosed. Said RP-HPLC methods employ wide pore silica gel reverse-phase columns and solvent systems containing acetonitrile as the organic modifier and either heptafluorobutyric acid or trifluoroacetic acid as the organic acid.The invention further concerns processes for purifying recombinant IFN-.beta. incorporating said improved RP-HPLC methods.The invention further concerns recombinant IFN-.beta. purified by said RP-HPLC methods, or recovered and/or purified by processes incorporating said RP-HPLC.
Abstract: The invention features a novel hybrid interferon species that comprises a chain of 161 and/or 162 amino acids. The hybrid is novel not only for its new structure, but also because the hybrid comprises a shortened or truncated segment of alpha interferon, and hence, an entirely new interferon species which is not occurring in nature.
Abstract: This invention relates to a vaccine for the immunization of a vertebrate, comprising:an avirulent derivative of a pathogenic microbe that expresses a recombinant gene derived from a pathogen of said vertebrate it being provided that said avirulent microbe does not normally exchange genetic material with said pathogen, to produce an antigen capable of inducing an immune response in said vertebrate against said pathogen.
Abstract: There is disclosed a method of determining the presence of incompatibility-reaction-causing substances in blood products. There is also disclosed a method of inactivating incompatibility-reaction-causing substances in blood products to be applied therapeutically and prophylactically. For this purpose, a fraction obtained from human or animal blood is treated with pancreas enzymes bound to water insoluble carrier material and, optionally, the fraction is subjected to further fractionation and concentration.
Abstract: This invention provides for administering to donor animals a substance that generates both anti-viral agents, such as interferon, in the blood and anti-bacterial or antitoxic antibodies. This is done at a certain time before recovery of plasma so that both the anti-viral substance (interferon), and anti-bacterial or antitoxic antibodies are substantially maximized. In the case of non-human animals the blood is recovered from animals to be slaughtered and plasma containing both the interferon and anti-bacterial (antitoxic/antibodies) is separated, thereby providing a significant quantity of scarce serum inexpensively.
Abstract: Novel hybrid interferons are produced which are derived from lymphoblastoid interferons .alpha.-2 and .alpha.-3 belonging to the interferon .alpha.B and .alpha.D groups, respectively. The novel hybrid interferons possess valuable antiviral and antiproliferative properties.
Type:
Grant
Filed:
June 5, 1986
Date of Patent:
December 5, 1989
Assignee:
Ciba-Geigy Corporation
Inventors:
Francois Meyer, Albert Hinnen, Andreas Meister, Markus G. Grutter, Sefik Alkan
Abstract: Infections in mammalian hosts may be treated therapeutically or prophylactically with an effective amount of at least one lymphokine before or after host infection, the amount being sufficient to achieve at least 50% protection of the host. Preferably, the lymphokine is IL-2 or a combination of TNF and IL-2 or TNF and IFN-.gamma.. Also, preferably the infection is bacterial and is being treated prophylactically. The combination of TNF and IL-2 or TNF and IFN-.gamma. is administered in synergistically effective amounts.
Abstract: There is provided genetically engineered bovine interferon of the IFN-.alpha.-type and various sub-types thereof. There is further provided a double stranded DNA molecule which includes DNA encoding BoIFN-.alpha. A, BoIFN0.alpha. B, BoIFN-.alpha. C, and BoIFN-.alpha. D, and cloning vehicles including such DNAs. There are further provided cells including such DNA and a process for the production of such types of BoIFN based on the use of such cells. Furthermore, there is also provided a method for the identification of a bovine IFN-.alpha. DNA sequence.
Type:
Grant
Filed:
April 9, 1985
Date of Patent:
October 31, 1989
Assignee:
State of Israel, Prime Minister's Office, Israel Institute for Biological Research
Inventors:
Baruch Velan, Sara Cohen, Haim Grosfeld, Avigdor Shafferman
Abstract: E. coli deficient in protease activities, said activities being not inhibited with diisopropyl fluorophosphate, phenylmethylsulfonyl fluoride, N-.alpha.-tosyl-L-lysyl chloromethyl ketone, N-tosyl-L-phenylalanine chloromethyl ketone, ethylenediamine tetra-acetic acid, leupeptin, antipain, .alpha..sub.2 -macroglobulin or chymostatin, and being inhibited with zinc chloride or copper chloride is disclosed.This E. coli is useful as a host for creating a transformant capable of expressing an exogenous protein or polypeptide.The protein or polypeptide expressed by the transformant may be extracted and purified with a quite low level of decomposition.
Abstract: A genomic DNA molecule having the nucleic acid sequence set forth in FIG. 1 and encoding an antigenic protein derived from Eimeria tenella has been isolated. The protein has a molecular weight of about 25,000 daltons and is composed of two polypeptides joined by a disulfide bond. One of the polypeptides is characterized by a molecular weight of about 17,000 daltons and by a blocked N-terminal amino acid and having the amino acid sequence set forth in FIG. 1. The other polypeptide is characterized by a molecular weight of about 8,000 daltons and has the amino acid sequence set forth in FIG. 1.A cDNA molecule encoding the 25,000 dalton polypeptide with a continuous amino acid sequence has been inserted into expression vectors capable of expressing the 25,000 dalton polypeptide directly or as a fused polypeptide. The polypeptides produced are used in vaccines to immunize chickens against infection by Eimeria tenella.
Type:
Grant
Filed:
December 6, 1985
Date of Patent:
October 17, 1989
Assignee:
Solvay & Cie, S.A.
Inventors:
William H. Andrews, Virginia M. Brothers, James G. Files, Irene Kuhn, Michael T. McCaman, Leland S. Paul, Stacey R. Sias, Thomas C. Gore, Karel Z. Newman, Jr., John L. Tedesco
Abstract: Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R donotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.
Abstract: A composition of matter consisting of recombinant human immune interferon having a near-UV circular dichroic spectrum in aqueous solution at neutral pH with positive bands at about 259 nm, 266 nm, 280 nm, and 287 nm, and with shoulders at about 270 nm and 292 nm. Also disclosed is a method for purifying human immune interferon in which proper refolding of the interferon is accomplished by unfolding in a denaturant, such as urea, dilution in ammonium acetate to approximately 0.18 mg/ml of interferon (or less), and dialysis of the solution. The properly folded, purified product which results has a four- to eight-fold greater activity than the aggregate which otherwise results.
Abstract: A purified form of a DNA virus which has the following characteristics: molecular weight greater than 2.times.10.sup.6 Daltons; substantial immunoreactivity towards an anti-HBsAg monoclonal antibody obtained from cell line ATCC HB 8058; substantially no immunoreactivity towards an anti-HBsAg monoclonal antibody obtained from cell line ATCC CRL 8018; concentration dependent immunoreactivity towards polyclonal IgG anti-HBsAg antibodies, which increases with increased concentration of said DNA virus; discrete particulate form when observed by immunoelectron microscopy in the presence of IgM antibodies from cell line ATCC HB 8058; the DNA of said virus showing hybridization with DNA from hepatitis B viral DNA; and said DNA virus showing, in chimpanzees, infectivity having the characteristics of non A, non B hepatitis.
Type:
Grant
Filed:
February 8, 1984
Date of Patent:
September 26, 1989
Assignees:
The General Hospital Corporation, The Albert Einstein College of Medicine of Yeshiva University
Abstract: Monoclonal antibodies directed against the 47 kDa major outer membrane surface immunogen of virulent Treponema pallidum were used to select E. coli recombinant clones expressing the 47 kDa immunogen. The phenotype of the clones was dependent on the presence of recombinant plasmid in the host cell. Southern hybridization revealed thatThe United States government may have rights in the substance of this patent because of developmental work supported by the U.S. Department of Health and Human Services in the form of research grants 1-R01-AI-16692 and 1-R01-AI-17366 from NIH-NIAID.
Type:
Grant
Filed:
September 30, 1986
Date of Patent:
September 19, 1989
Assignee:
Board of Regents, The University of Texas System
Abstract: This invention relates to a process for the microbial degradation of cellulosic material. More specifically, this invention relates to a process for the digestion of cellulose by a microbe capable of carrying out the cellulolytic combined nitrogen.
Type:
Grant
Filed:
September 25, 1984
Date of Patent:
August 29, 1989
Assignee:
Research Corporation
Inventors:
John B. Waterbury, Charles B. Calloway, Ruth D. Turner
Abstract: Retroviral vaccines are provided comprising incompetent retroviruses containing defective RNA produced by growing viral transformed cells in the presence of interferon. The resulting defective viruses by themselves or in combination with interferon can be used as vaccines for immunizing viral sensitive hosts against infection. A novel feline interferon is produced in culture with cells infected with the defective non-infectious retroviruses.
Abstract: The invention relates to compositions containing an inhibitor of the Golgi enzyme .alpha.-mannosidase II and which may contain an interferon or interferon inducer and to methods of preventing and treating diseases, such as proliferative diseases, viral infections and neoplastic growth and metastasis with the compositions.
Abstract: Combinations of 9-(1,3-dihydroxy-2-propoxymethyl) guanine or a pharmaceutically acceptable salt thereof, with .beta.-interferon show a surprisingly high degree of synergism in their activity against viral infections.
Abstract: A sustained-release preparation of indomethacin or interferon comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, gelatin, and a mixture thereof. The preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.